This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Leukemia Open Access 27 March 2024
-
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
Blood Cancer Journal Open Access 15 March 2024
-
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial
Bone Marrow Transplantation Open Access 15 July 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.
Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683–93. https://doi.org/10.1053/j.seminoncol.2012.09.005.
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115:3224–30. https://doi.org/10.1182/blood-2009-11-251595.
Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S, et al. Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015;21:941–4. https://doi.org/10.1016/j.bbmt.2015.01.020.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–64. https://doi.org/10.1016/S1470-2045(09)70225-6.
Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006;12:560–5. https://doi.org/10.1016/j.bbmt.2005.12.034.
Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary M, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17:164–73. https://doi.org/10.1016/S1470-2045(15)00462-3.
Sibai H, Falcone U, Deotare U, Michelis FV, Uhm J, Gupta V, et al. Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. Biol Blood Marrow Transplant. 2016;22:2270–5. https://doi.org/10.1016/j.bbmt.2016.08.030.
Russell JA, Irish W, Balogh A, Chaudhry MA, Savoie ML, Turner AR, et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant. 2010;16:509–14. https://doi.org/10.1016/j.bbmt.2009.11.017.
Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–6. https://doi.org/10.1200/JCO.2012.44.3523.
Solomon SR, Sanacore M, Zhang X, Brown S, Holland K, Morris LE, et al. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2014;20:1828–34. https://doi.org/10.1016/j.bbmt.2014.07.020.
Kanakry JA, Kasamon YL, Bolanos-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, et al. Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant. 2013;19:1514–7. https://doi.org/10.1016/j.bbmt.2013.07.013.
Author contributions
UD: Conception and design of study, data collection, data analysis, manuscript preparation. EA: Statistical analysis and manuscript preparation. DL, FM, DK, ST, JL: Manuscript preparation. HM: Data analysis, manuscript preparation. AV: Conception and design of study, data analysis, manuscript preparation, program leader and senior author.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Presented in part at the 58th American Society of Hematology Annual Meeting in San Diego, California, 2–6 December 2016 and at the American Society of Blood and Marrow Transplantation meeting at Orlando, Florida, 22–26 February 2017.
Rights and permissions
About this article
Cite this article
Deotare, U., Atenafu, E.G., Loach, D. et al. Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. Bone Marrow Transplant 53, 361–365 (2018). https://doi.org/10.1038/s41409-017-0053-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-017-0053-9
This article is cited by
-
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Leukemia (2024)
-
PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation
Blood Cancer Journal (2024)
-
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial
Bone Marrow Transplantation (2022)
-
Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide
Bone Marrow Transplantation (2021)
-
Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia
Leukemia (2020)